{"id":72011,"date":"2024-07-15T23:00:10","date_gmt":"2024-07-15T23:00:10","guid":{"rendered":"http:\/\/b553c8a00f3347fbdef9871461a097da"},"modified":"2024-07-15T23:00:10","modified_gmt":"2024-07-15T23:00:10","slug":"new-drug-for-stiff-person-syndrome-granted-designation-to-speed-up-development-thrilled-for-the-community","status":"publish","type":"post","link":"https:\/\/wp.timesamerica.net\/new-drug-for-stiff-person-syndrome-granted-designation-to-speed-up-development-thrilled-for-the-community\/","title":{"rendered":"New drug for stiff person syndrome granted designation to speed up development: \u2018Thrilled for the community\u2019"},"content":{"rendered":"\n
Patients with stiff person syndrome<\/u><\/span> are one step closer to having access to a new treatment.<\/p>\n Kyverna Therapeutics\u2019 new drug, KYV-101, has been designated by the U.S. Food and Drug Administration (FDA) a Regenerative Medicine Advanced Therapy (RMAT), the company announced on Monday.<\/p>\n A drug is eligible for RMAT designation if it is “intended to treat, modify, reverse or cure a serious or life-threatening disease<\/u><\/span> or condition” and if “preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition,” according to the FDA\u2019s website.<\/p>\n STIFF PERSON SYNDROME PATIENTS SHARE WHAT IT\u2019S LIKE TO LIVE WITH THE RARE DISEASE<\/u><\/strong><\/span><\/p>\n One of the benefits of RMAT is that Kyverna will be able to work closely with the FDA to help support accelerated development, review and approval, according to the company.<\/p>\n The FDA\u2019s decision was based on positive results from clinical trials with patients, a company press release stated.<\/p>\n